| 0.4846 -0.009 (-1.82%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.77 | 1-year : | 0.95 |
| Resists | First : | 0.66 | Second : | 0.81 |
| Pivot price | 0.54 |
|||
| Supports | First : | 0.41 | Second : | 0.34 |
| MAs | MA(5) : | 0.49 |
MA(20) : | 0.56 |
| MA(100) : | 0.69 |
MA(250) : | 0.81 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 38.3 |
D(3) : | 38.7  |
| RSI | RSI(14): 36.2 |
|||
| 52-week | High : | 1.49 | Low : | 0.41 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ APRE ] has closed above bottom band by 17.3%. Bollinger Bands are 7.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.52 - 0.53 | 0.53 - 0.53 |
| Low: | 0.45 - 0.46 | 0.46 - 0.46 |
| Close: | 0.48 - 0.49 | 0.49 - 0.49 |
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Fri, 30 Oct 2026
Aprea Therapeutics, Inc. (APRE) Seasonal returns chart - Yahoo Finance UK
Sat, 24 Oct 2026
Aprea Therapeutics, Inc. Estimates – NASDAQ:APRE - TradingView
Sun, 18 Oct 2026
Aprea Therapeutics Q3 2026 Earnings Date and Estimates - MarketBeat
Mon, 05 Oct 2026
Aprea Therapeutics to Present at October Conferences - The Manila Times
Fri, 28 Aug 2026
Aprea Therapeutics reports patent portfolio of 58 patents - Investing.com
Tue, 25 Aug 2026
Aprea Therapeutics records second consecutive surge, jumping another 22% (APRE:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 7.9e+006 (%) |
| Held by Institutions | 9.1 (%) |
| Shares Short | 617 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.32e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -255 % |
| Return on Assets (ttm) | 25.5 % |
| Return on Equity (ttm) | -27.8 % |
| Qtrly Rev. Growth | 5180 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -28.32 |
| EBITDA (p.s.) | -4.1227e+006 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.25 |
| Dividend | 0 |
| Forward Dividend | 508840 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|